Suppose neuroscience and neuropharmacology was perverted to produce
drugs that damage society. I'm not thinking of cocaine or LSD, I'm
thinking of drugs that raise people's sex drives.
Until recently, scientists would have dismissed any drug that enhanced
sex drive as a fraud.
But no longer.
First a drug called PT141, developed by Concordia University and
Palatin Technologies was developed which increased sexual behavior of
female rats. This drug is soon to be tried on humans.
There there was a report on a brain tumor that converted an ordinary
man into a sex maniac (new scientist).
Articles on both of these news items are appended below.
To me they show that the pandora's box of sex drugs is in our future.
Nightmare experience for man whose cancer turned him into a pedophile
December 31 2002
New York: A brain tumour turned a 40-year-old schoolteacher into an
uncontrollable sex addict and pedophile, a meeting of experts has been
When the tumour was removed, the man's obsession disappeared. But by
then the teacher had been evicted from his house and found guilty of
Russell Swerdlow and Jeffrey Burns, neurologists at the University of
Virginia, believe it is the first reported case linking brain cancer
They told the annual meeting of the American Neurological Association
in New York that the tumour was in a brain region that did not affect
Dr Swerdlow said: "We're dealing with the neurology of morality here.
It's one of those areas where you could have a lot of damage and a
doctor would never suspect something's wrong."
The teacher had secretly started visiting child pornography websites
and soliciting prostitutes, activities he had never engaged in before.
Dr Swerdlow said that while the man felt his new behaviour was
unacceptable, in his words, the "pleasure principle overrode his
When the man's wife discovered he had been making subtle sexual
advances towards young children, he was legally evicted from his house
and found guilty of child molestation.
A judge ruled he had to pass a 12-step Sexaholics Anonymous
rehabilitation course or face going to jail. But the man was expelled
from the program after asking women on the course for sex, the meeting
The evening before he was due to receive a prison sentence he took
himself to a hospital. He said he was suffering headaches and feared
he would rape his landlady.
After being remanded to psychiatric care, he complained of balance
problems, and a MRI brain scan revealed an egg-sized tumour. Seven
months after the tumour was removed, and having completed the
Sexaholics Anonymous course, the man returned home and resumed a
In October last year the headaches returned and he started collecting
pornography again. Another scan showed that the tumour had regrown,
but again its removal caused the man's sex-obsessed behaviour to
Dr Burns said: "He wasn't faking, but if someone argues that every
pedophile needs an MRI, the difference in this case was that the
patient had a normal history before he acquired the problem."
David Rosenfield, a behavioural neurologist at Baylor College of
Medicine in Houston, Texas, said more research was needed on whether
other problems with the orbifrontal cortex region of the brain might
be linked to pedophilia.
The case was reported by New Scientist magazine's online news service.
This story was found at:
New sex drug makes girls want sex and causes girls to arouse boys
October 26, 2001 - Palatin Technologies with Concordia University in
PT141 increases female desire; PT-141 enhances sexual behavior in
females, making them heighten sexual arousal in their male partners.
Palatin Technologies' PT-141 increases sexual behavior in female
animals Preclinical studies have demonstrated that PT-141
significantly enhances sexual behavior in female rodents.
Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an
investigational treatment for male and female sexual dysfunction. Data
from preclinical efficacy studies of PT-141 will be presented
Saturday, October 27th, at the Female Sexual Function Forum (FSFF)
Meeting in Boston, MA.
The studies were performed by Palatin scientists in collaboration with
Concordia University in Montreal. Annette M. Shadiack, PhD, Director,
Biological Research at Palatin, will present the results.
The studies' objectives were to evaluate PT-141's ability to enhance
sexual behavior in female rodents. The studies were designed to allow
for the evaluation of PT-141's effect on a variety of normal
precopulatory sexual behaviors that are used by female rodents to
heighten sexual arousal in their male partners. Female animals given
PT-141 showed a significant, dose-responsive increase in a variety of
these precopulatory sexual behaviors and actively solicited sexual
contact from the males. Importantly, PT-141 treatment increased the
female rodents' desire to copulate.
"These data suggest that stimulation of melanocortin receptors in the
brain by PT-141 selectively increased motivation for sexual activity
in female rodents. The results indicate that PT-141 has potential to
offer a unique treatment for women with desire disorders" said Dr.
Perry Molinoff, M.D., Executive Vice President of Research &
Development of Palatin said, "We are very excited about these results,
which, in combination with the positive safety results from our Phase
1 clinical study in men, provide the basis for advancing this
investigational drug into Phase 2 efficacy trials in women with Female
Sexual Dysfunction (FSD) early next year."
Palatin recently completed a Phase 1 safety trial with PT-141 in men
that demonstrated a positive safety profile. PT-141 was well tolerated
at all doses, there were no significant changes in blood pressure,
heart rate or respiration rate, and investigators reported no serious
side effects. A Phase 2A efficacy study of patients with erectile
dysfunction is scheduled to begin later this year.
PT-141 is a peptide analog of the neuropeptide hormone a-MSH
(a-melanocyte-stimulating hormone). Scientists have determined that
receptors for this class of molecules (melanocortin receptors) play a
role in several behaviors including appetite and sexual arousal.
Recent findings indicate the effects on sexual function may be
stimulated through melanocortin receptors in the brain. As a result,
Palatin believes PT-141 has the potential to offer a unique treatment
for both male and female sexual dysfunction.
Palatin Technologies, Inc. is a development-stage biopharmaceutical
company. The company is currently conducting clinical investigations
with its lead drug, PT-141, for the treatment of erectile dysfunction,
and is developing additional therapeutic compounds discovered using
its enabling peptide platform technology, MIDAS. Additionally, Palatin
is developing a product for infection imaging, LeuTech(TM), based on a
proprietary radiolabeled monoclonal antibody.